Insider Trading News
-
U.S. Securities and Exchange Commission Enforcement Director Robert Khuzami said the agency’s investigations haven’t been harmed by a policy of discarding documents related to initial inquiries.
-
U.S. regulators approved two sets of guidelines that banks including Citigroup Inc. and JPMorgan Chase & Co. will have to follow in drafting plans to protect the broader economy in the event of their own collapse.
-
Galleon Group LLC co-founder Raj Rajaratnam’s arrest for insider trading in October 2009 made a former Advanced Micro Devices Inc. employee afraid the U.S. suspected him of passing tips to the fund, he said.
-
An ex-Advanced Micro Devices Inc. employee told jurors that the 2009 arrest of Galleon Group LLC co-founder Raj Rajaratnam on insider-trading charges caused him to fear that he was suspected of passing tips to the hedge fund.
-
Andrew Liang, accused of joining an insider-trading scheme with his father, a U.S. Food and Drug Administration chemist, was charged with possessing child pornography found in the course of the fraud investigation.
-
The European Union is considering listing “specific examples of strategies using algorithmic trading and high-frequency trading” that should be banned and punished by regulators as market manipulation.
-
Donald Longueuil, a former junior portfolio manager at SAC Capital Advisors LP, agreed to settle a civil suit filed by the U.S. Securities and Exchange Commission.
-
The agency that oversees the U.S. municipal-bond market delayed proposed rules for financial advisers until the Securities and Exchange Commission defines who will be subject to the regulation.
-
Galleon Group LLC co-founder Raj Rajaratnam, convicted of directing the biggest-ever hedge fund insider trading scheme, may face a stiffer sentence after telling a court official he still wasn’t “clear” that what he did was wrong.
-
A former Sequenom Inc. patent agent and his brother were sentenced to three years of probation after they pleaded guilty to conspiring to trade stock options in the biotechnology company’s shares using inside information.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page